Drug intelligence / Profile preview

AG-3365

Development stage: Preclinical
Lead developer: Angarus Therapeutics
Modality: Small Molecules

Overview

AG-3365 is a small molecule drug in preclinical development by Angarus Therapeutics. It acts as an inhibitor of ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase family member 1), a target involved in immune regulation. The primary therapeutic area for AG-3365 is immune system diseases, with active investigation for autoimmune diseases. By inhibiting ENPP1, the drug aims to modulate immune responses, potentially offering benefit in conditions characterized by dysregulated immunity[1].

Targets

ENPP1

Beyond the preview

Go deeper on AG-3365.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AG-3365.

Explore the full profile